Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Novogen — Australia Biotech Invest Annual Conference 2016
10 slides from Kazia Therapeutics's conference presentation, Oct 26, 2016
Slide 1: Novogen Limited Presentation to Australia Biotech Invest Annual Conference
Novogen Limited Presentation to Australia Biotech Invest Annual Conference Dr James Garner Melbourne, VIC Chief Executive Officer 26th October 2016 [email protected] NOVOGEN Version 1.0
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual
Slide 3: Novogen is a biotech company dedicated to driving sustainable, long-term growth in shareholder value
Novogen is a biotech company dedicated to driving sustainable, long-term growth in shareholder value Focus on unmet medical need Financially sound Pipeline of novel therapies, targeting Listed on ASX and NASDAQ, with cash oncology patients poorly served by runway sufficient to drive existing existin
Slide 4: Listed on ASX and NASDAQ (via ADRs) and well-funded for current operations
Novogen is listed on ASX and NASDAQ (via ADRs) and is well-funded for current operations Share Price (US$) 3.00 NVGN Market Capitalisation AU$ 41 million NASDAQ Biotech Index 2.50 ASX: NRT Listing 2.00 NASDAQ: NVGN (1:25 ratio) Average Daily Volume ASX: ~570,000 /day 1.50 NASDAQ: ~50,000 ADRs /day 1
Slide 5: Oncology-focused, with a robust in-house pipeline and strong partnering aspirations
Novogen is oncology-focused, with a robust in-house pipeline and strong partnering aspirations Assets from internal discovery engines Programs taken through Molecules partnered with preclinical and clinical pharma / large biotech for development, generally to phase III development Assets in-licensed
Slide 6: Configured for efficient and effective drug development
Novogen is configured for efficient and effective drug development 2015 2016 Early-stage, discovery-focused Clinical-stage, development-biotech with mixed portfolio of focused biotech, dedicated to projects and limited clarity in path oncology, and highly focused on to value generation value generat
Slide 7: Strong management team with international experience in big pharma
Novogen has a strong management team with international experience in big pharma Dr James Garner Chief Executive Officer & Managing Director Physician / MBA; Extensive pharma drug development experience Dr David Brown Chief Scientific Officer Twenty years of drug discovery and development experience
Slide 8: Pipeline includes three molecules, with two entering the clinic over the next nine months
Novogen’s pipeline includes three molecules, with two entering the clinic over the next nine months First-in-class program targeting cancer-specific tropomyosin isoform in cytoskeletal microfilaments ATM Platform of cancer cells, leading to apoptosis First-in-class program based on earlier clinicall
Slide 9: Oncology-focused, with a robust in-house pipeline and strong partnering aspirations
Novogen is oncology-focused, with a robust in-house pipeline and strong partnering aspirations Assets from internal discovery engines Programs taken through Molecules partnered with preclinical and clinical pharma / large biotech for development, generally to phase III development Assets in-licensed
Slide 10: NOVOGEN
NOVOGEN
Novogen — Australia Biotech Invest Annual Conference 2016 on 6ix